Encompass Health reports results for third quarter 2026

Encompass Health reported Q3 2026 revenue of $1.61 billion, up 8.9% year over year, and adjusted EBITDA of $346.6 million, up 15.5%; adjusted EPS rose 23.6% to $1.52. The company raised its 2026 guidance, setting revenue at $6.45–$6.50 billion, adjusted EBITDA at $1.395–$1.415 billion, and adjusted EPS at $6.23–$6.37. Discharges increased 5.7% to 69,605, while operating cash flow rose 33.7% to $362 million.

Analysis

The earnings quality is better than headline growth alone suggests: pricing per discharge and same-store volume both contribute, while salary-cost growth appears to have lagged revenue growth this quarter. But do not annualize the margin improvement until management clarifies labor, staffing, and payer mix on tomorrow’s call. The updated EBITDA midpoint is only about 1.8% above the prior midpoint, and implies Q4 EBITDA modestly above Q3; the key near-term test is whether that requires a favorable seasonal mix or is repeatable operating leverage.

Expansion is a two-sided story. New capacity can extend growth, but nine-month investment spending materially exceeds maintenance capex, so adjusted free cash flow should not be read as fully distributable cash. Debt also increased, and distributions to noncontrolling interests reduce the portion of operating cash economics accruing to EHC shareholders. Receivables have risen faster than year-to-date revenue; this may reflect growth, but makes collection timing, denials, and Medicare review activity important checks rather than assuming cash conversion is clean.

Over 6–18 months, reimbursement policy, labor availability, and successful ramp-up of new beds matter more than the current quarter’s beat. The contrarian risk is that investors extrapolate Q3 margin momentum while overlooking capital intensity and payer-related working capital. No valuation or consensus data are supplied, so the result alone does not establish that the shares are cheap or that the post-release move is underpriced.

Key Decisions for Investors

• Tactical bias: favor EHC on a post-earnings pullback rather than chase the initial reaction. Reassess after the Oct. 29 call; seek confirmation that same-store volume and pricing remain healthy without further labor-cost acceleration.
• Use the call as the 1–3 month catalyst check: monitor labor expense per discharge, payer mix, Medicare denials/appeal delays, and receivable aging. A sustained same-store discharge slowdown or a guidance reduction would falsify the growth thesis.
• Treat the raised outlook as a modest estimate reset, not proof of a new earnings-growth slope. Compare subsequent quarters’ EBITDA growth with revenue and labor-cost growth; margin giveback would argue for reducing exposure.
• Avoid framing adjusted free cash flow as excess capital available for buybacks: verify full-year growth capex, debt trajectory, and cash distributions to noncontrolling interests in the 10-Q before underwriting shareholder returns.